Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Surgical Oncology

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/ASO.2004.03.019PMID 14761920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Simplified Procedure for Continuous Intraoperative External Monitoring of Systemic Leakage during Isolated Limb Perfusion

  2002cited by this paper
• Isolated limb perfusion for melanoma

  2002cited by this paper
• Isolated limb perfusion in locally advanced cutaneous melanoma.

  2002cited by this paper
• TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

  2000cited by this paper
• Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

  2000cited by this paper
• Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

  1999cited by this paper
• Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study.

  1999cited by this paper
• Are Locoregional Cutaneous Metastases in Melanoma Predictable?

  1999cited by this paper
• Hyperthermic regional perfusion for melanoma and sarcoma of the limbs.

  1999cited by this paper
• Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells

  1997cited by this paper
• Systemic leakage and side effects of tumor necrosis factor alpha administration via isolated limb perfusion can be manipulated by flow rate adjustment.

  1996cited by this paper
• Systemic Leakage and Side Effects of Tumor Necrosis Factor α Administered via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment

  1996cited by this paper
• Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 °C hyperthermia

  1995cited by this paper
• Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia.

  1995cited by this paper
• Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion.

  1993cited by this paper
• Low‐dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion

  1993cited by this paper
• Natural history and selective management of in transit melanoma

  1990cited by this paper
• Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture.

  1988cited by this paper
• Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

  1982cited by this paper
• Survival and regional disease control after isolation‐perfusion for invasive stage I melanoma of the extremities

  1976cited by this paper
• Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion.

  1974cited by this paper
• Hyperthermic perfusion with chemotherapy for cancers of the extremities.

  1969cited by this paper

• A mirror of metastatic destiny – A case series of cutaneous metastases

  2024cites this paper
• Technical considerations for isolated limb perfusion: A consensus paper.

  2024cites this paper
• Isolated limb perfusion for locally advanced melanoma in the immunotherapy era.

  2022cites this paper
• Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma.

  2021cites this paper
• Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature

  2021influential citation
• Surgery for Metastatic Melanoma: an Evolving Concept

  2019cites this paper
• Hyperthermic Regional Perfusion for Melanoma of the Limbs

  2018cites this paper
• Diagnosis and treatment of in-transit melanoma metastases.

  2017cites this paper
• Chapter 5 – Therapy of Melanoma

  2017cites this paper
• Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.

  2017cites this paper
• Two Decades of Tumor Necrosis Factor-α and Melphalan Based Isolated Limb Perfusion

  2016cites this paper
• Armed antibodies for cancer treatment: a promising tool in a changing era

  2014cites this paper
• Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion?

  2014cites this paper
• Subcutaneous metastases from melanoma: a discussion of clinical experience.

  2014cites this paper
• Cutaneous Melanoma − Surgical Treatment

  2013cites this paper
• Current management of melanoma.

  2013cites this paper
• Isolierte Extremitätenperfusion bei Melanomen

  2013cites this paper
• Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?

  2012cites this paper
• Terapie locoregionali e chirurgia oncologica

  2011cites this paper
• Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha

  2011cites this paper
• 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters

  2011cites this paper
• Initial experiences with isolated limb perfusion for unresectable melanoma of the limb

  2011cites this paper
• Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion

  2011cites this paper
• An in vitro and in vivo investigation of the biological behavior of a ferrimagnetic cement for highly focalized thermotherapy

  2010cites this paper
• Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model.

  2010cites this paper
• Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.

  2010influential citation
• Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.

  2010cites this paper
• Фактор некроза опу холи человека имеет высокий противоопухолевый потенциал. В обзоре представлены сведения о клинических испытаниях препаратов на основе фактора некроза опухоли человека, которые прово- дятся в разных странах. Ключевые слова: фактор некроза опухоли, онкология, клинические испытания.

  2010cites this paper
• Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases

  2010cites this paper
• The dual role of tumor necrosis factor (TNF) in cancer biology.

  2010cites this paper
• Locoregional Therapies and Surgical Oncology

  2010cites this paper
• Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.

  2009cites this paper
• [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].

  2009cites this paper
• Surgery and radiotherapy in the treatment of cutaneous melanoma

  2009cites this paper
• [Study and treatment of locally advanced melanoma].

  2009cites this paper
• Melanoma localmente avanzado. Estudio y tratamiento

  2009cites this paper
• Experiencia en el tratamiento de satelitosis y metástasis cutáneas en tránsito de melanoma con interleucina 2 intralesional

  2009cites this paper
• The European approach to in-transit melanoma lesions

  2008cites this paper
• History of regional chemotherapy for cancer of the extremities

  2008cites this paper
• Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma

  2008cites this paper
• Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors

  2008cites this paper
• Isolated limb perfusion for melanoma.

  2008cites this paper
• TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial

  2008cites this paper
• Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.

  2007cites this paper
• Isolated Limb Perfusion for Melanoma in Transit Metastases

  2007cites this paper
• Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma.

  2007cites this paper
• Current immunotherapeutic strategies in malignant melanoma.

  2007cites this paper
• Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.

  2007cites this paper
• [Therapy of cutaneous metastases of malignant melanoma].

  2006cites this paper
• Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

  2006cites this paper
• Possibilities of improving the parameters of hyperthermia in regional isolated limb perfusion using epidural bupivacaine and accurate temperature measurement of the three layers of limb tissue

  2006cites this paper
• Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.

  2006cites this paper
• Therapie von Hautmetastasen beim malignen Melanom

  2006cites this paper
• Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.

  2006cites this paper
• Isolated Limb Perfusion With Melphalan and Tumor Necrosis Factor α for Advanced Melanoma and Soft-Tissue Sarcoma

  2006cites this paper
• Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-α

  2006cites this paper
• Isolated limb perfusion in regional melanoma.

  2006cites this paper
• Superficial hyperthermia combined with hypofractionated radiotherapy of malignant melanoma metastases to skin and lymph nodes

  2006cites this paper
• Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities

  2006cites this paper
• TNF-α in Cancer Treatment : Molecular Insights , Antitumor Effects , and Clinical Utility

  2006cites this paper
• Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.

  2006cites this paper
• TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

  2006cites this paper
• TNF dose reduction in isolated limb perfusion.

  2005cites this paper
• Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

  2005cites this paper
• Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better?

  2005cites this paper
• Tumor necrosis factor, cancer and anticancer therapy.

  2005cites this paper
• One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases

  2004cites this paper
• TNFa-based isolated hyperthermic limb perfusion (HILP) in the treatment of limb recurrent melanoma: update 16 years after its first clinical application.

  2004cites this paper
• Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity

  2004cites this paper
• TNFα-Based Isolated Hyperthermic Limb Perfusion (HILP) in the Treatment of Limb Recurrent Melanoma: Update 16 Years after Its First Clinical Application

  2004cites this paper
• Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?

  2004cites this paper